Age-related macular degeneration – Diagnostics – Overview of Information and Clinical Research

Spotting age-related macular degeneration early can be the difference between preserving your central vision and facing rapid vision loss. While this common eye condition doesn’t lead to complete blindness, understanding when and how to get tested is essential for protecting your ability to read, recognize faces, and maintain independence.

Introduction: Who Should Undergo Diagnostics and When

Age-related macular degeneration, often called AMD, affects the sharp, straight-ahead vision you need for everyday activities. One of the trickiest aspects of this condition is that it often develops silently, especially in its early stages. Many people don’t realize anything is wrong with their eyes until they’ve already lost some central vision. This is why regular diagnostic testing becomes so important as you get older.^[1]

If you’re age 55 or older, you should start thinking about regular eye exams even if your vision seems fine. The risk of developing AMD increases significantly with age, and people who are 75 or older face nearly a 30% chance of developing the advanced form of the disease.^[4] But age isn’t the only factor that should prompt you to seek diagnostic testing.

Certain risk factors make it more urgent to have your eyes examined. If you have a family history of AMD, meaning a parent or sibling has been diagnosed with the condition, you’re at higher risk and should discuss screening with your eye doctor earlier. People who smoke, have high blood pressure, are overweight, or eat a diet high in saturated fats also face increased risk.^[1]^[2] Being of Caucasian descent is another known risk factor that medical professionals look at when determining how often you should be tested.^[1]

You shouldn’t wait for symptoms to appear before seeking testing. Early AMD typically causes no noticeable vision changes at all. By the time you notice problems like blurred or wavy vision, the disease may already be in an intermediate or late stage.^[1] This is why eye health experts emphasize the importance of routine exams, particularly for those at higher risk.

⚠️ Important

If you notice that straight lines suddenly look wavy or bent, or if you see a blurry or dark spot in the center of your vision, contact your eye doctor immediately. These are warning signs of late-stage AMD, particularly the wet form, which can cause rapid vision loss if not treated quickly.^[1]

If you’ve already been diagnosed with early or intermediate AMD in one eye, monitoring becomes critical. You’ll need more frequent check-ups to catch any progression early, and you’ll want to protect your other eye. Even if you have no symptoms yet, your doctor can see changes happening inside your eye during a comprehensive examination.^[1]

Classic Diagnostic Methods for Identifying AMD

Diagnosing age-related macular degeneration involves several different tests and examinations. These methods help eye doctors see what’s happening at the back of your eye, where the macula—the part of the retina responsible for central vision—is located. The retina is light-sensitive tissue that lines the back of your eye, and the macula is its central portion that gives you sharp, detailed vision.^[1]

Dilated Eye Examination

The most fundamental test for AMD is a dilated eye exam. During this examination, your eye doctor puts special drops in your eyes to widen (dilate) your pupils. This allows them to look inside your eye and examine the retina and macula more thoroughly. The dilation typically lasts several hours, during which your vision may be blurry and you’ll be more sensitive to light.^[1]^[11]

When examining the back of your eye, the doctor looks for specific signs of AMD. One of the earliest indicators is the presence of drusen, which are small yellow or white deposits that form under the retina. These protein and fat deposits appear as pale yellow spots during the examination. While small drusen are common as people age and may be harmless, larger or more numerous drusen can signal the development or progression of AMD.^[2]^[6]

In more advanced dry AMD, doctors look for areas where the retina has become noticeably thinner or damaged. This is called geographic atrophy, and it represents the late stage of dry AMD. In wet AMD, the examination may reveal signs of abnormal blood vessels or fluid buildup under the retina.^[2]^[6]

Amsler Grid Test

The Amsler grid is a simple but effective tool for detecting changes in your central vision. This test uses a grid of straight lines with a dot in the center. You cover one eye and look at the dot while paying attention to whether any of the lines appear wavy, broken, blurry, or if any areas seem missing or darkened.^[11]

This test is particularly useful for spotting the vision distortion that commonly occurs with AMD. If you have macular degeneration, straight lines may appear bent or wavy—a symptom that indicates damage to the macula. Some people also notice blank spots or blurry areas when looking at the grid. Your doctor may give you an Amsler grid to use at home so you can monitor your vision between appointments.^[1]^[11]

Fluorescein Angiography

Fluorescein angiography is an imaging test that helps doctors see the blood vessels in your retina in great detail. During this procedure, a special dye called fluorescein is injected into a vein in your arm. As the dye travels through your bloodstream and reaches the blood vessels in your eye, a special camera takes multiple photographs. These images highlight how blood flows through the vessels and can reveal problems like leaking, blockages, or abnormal new blood vessels growing where they shouldn’t.^[11]^[6]

This test is especially helpful for diagnosing wet AMD, where abnormal blood vessels grow beneath the retina and leak fluid or blood. The fluorescein dye shows exactly where these vessels are located and how severe the leakage is. The test can also detect changes in the retina’s structure that might not be visible during a standard eye exam.^[11]

Indocyanine Green Angiography

Similar to fluorescein angiography, indocyanine green angiography uses a different type of dye to examine blood vessels in the eye. This dye is particularly useful for seeing deeper layers of blood vessels beneath the retina, including those in the choroid, a layer of blood vessels that sits behind the retina. Sometimes this test is performed alongside fluorescein angiography to give doctors a more complete picture of what’s happening in different layers of the eye.^[11]^[6]

Optical Coherence Tomography (OCT)

Optical coherence tomography, or OCT, is a non-invasive imaging technique that creates detailed cross-sectional images of your retina. Think of it like an ultrasound, but instead of using sound waves, OCT uses light waves to capture extremely detailed pictures of the retina’s layers. This allows doctors to measure the thickness of the retina and see if there’s any fluid buildup or structural damage.^[6]^[12]

OCT has become one of the most valuable tools for diagnosing and monitoring AMD. It can detect subtle changes in the macula that might not be visible with other methods. For wet AMD, OCT is particularly useful because it can show fluid accumulation under or within the retina very clearly. The test is quick, painless, and doesn’t require any injections or dyes.^[6]

Reviewing Medical and Family History

Beyond physical examinations and imaging tests, your eye doctor will also ask detailed questions about your medical and family history. They’ll want to know if anyone in your family has had AMD, whether you smoke or have smoked in the past, and if you have other health conditions like high blood pressure or heart disease. All of these factors contribute to understanding your personal risk and help guide decisions about how often you should be monitored and what preventive steps you might take.^[2]

Diagnostics for Clinical Trial Qualification

When researchers conduct clinical trials for new AMD treatments, they need to carefully select participants who meet specific criteria. The diagnostic tests used to qualify patients for these trials are often more extensive and precise than those used in routine clinical care. Understanding these qualification procedures can be helpful if you’re considering participating in research studies.^[1]

Clinical trials typically require detailed imaging to classify exactly what type and stage of AMD a potential participant has. Both dry and wet forms have different treatment approaches being studied, so precise classification is essential. Researchers use many of the same diagnostic tools described earlier, but they often employ them more frequently and with stricter protocols.

OCT scans are almost always part of clinical trial screening because they provide objective, measurable data about the retina’s structure. Trial investigators need to document the extent of retinal thinning in dry AMD or measure the amount of fluid present in wet AMD. These baseline measurements help researchers track whether an experimental treatment is working over time. Serial OCT scans taken at regular intervals during the trial can show whether the macula is stabilizing, improving, or continuing to deteriorate.^[6]^[12]

Fluorescein angiography is frequently required for wet AMD trials. This test helps confirm the presence of choroidal neovascularization, which is the technical term for the abnormal blood vessels that characterize wet AMD. Researchers need to see exactly where these vessels are and how actively they’re leaking to determine if someone is a suitable candidate for a particular study. They may also use this test repeatedly during the trial to measure whether the treatment is successfully stopping the growth or leakage of these vessels.^[6]

Visual acuity testing—measuring how well you can see—is another standard requirement for clinical trial qualification. Trials often specify that participants must have vision within a certain range, neither too good nor too poor, to participate. This ensures that researchers can accurately measure whether the treatment improves, maintains, or fails to affect vision. The Snellen eye chart, where you read progressively smaller letters, is commonly used, although trials may use more sophisticated methods to measure subtle changes in vision.^[12]

In recent years, many AMD trials have also started requiring genetic testing to identify specific variants that might affect how someone responds to treatment. Certain genes are associated with higher risk of AMD or faster disease progression. Understanding a participant’s genetic profile helps researchers determine whether particular treatments work better for specific genetic subtypes of the disease. This is part of a movement toward personalized medicine, where treatments are tailored to individual characteristics.^[12]

⚠️ Important

Clinical trials often have strict eligibility requirements beyond just having AMD. You might be excluded if you have certain other eye conditions, specific health problems, or if you’re taking particular medications. Don’t be discouraged if you don’t qualify for one trial—many different studies are ongoing, and your doctor can help you explore other options if you’re interested in participating in research.^[1]

Trial participation usually requires more frequent monitoring than regular clinical care. You may need to visit the study site monthly or even more often for repeated diagnostic testing. This intensive monitoring allows researchers to catch any changes quickly and gather detailed data about how the treatment is affecting your eyes over time. While this requires more commitment from participants, it also means you’ll receive very close attention to your eye health throughout the study period.

Before enrolling in any clinical trial, you’ll go through a thorough informed consent process where researchers explain all the tests you’ll undergo, potential risks, and what’s expected of you as a participant. You’ll also learn whether you might receive a placebo (an inactive treatment used for comparison) or an active experimental treatment. All diagnostic results obtained during the trial are typically shared with your regular eye doctor so your overall care remains coordinated.^[1]

Prognosis and Survival Rate

Prognosis

The outlook for people with age-related macular degeneration varies significantly depending on which type and stage of the disease they have. Importantly, AMD is not a life-threatening condition, though it can profoundly affect quality of life. Complete blindness from AMD is extremely rare because the condition doesn’t affect peripheral (side) vision. Even people with advanced AMD retain their ability to see things off to the sides, which helps them maintain some independence.^[1]^[2]

For people with early-stage dry AMD, the prognosis is generally good. The disease often progresses very slowly over many years, and some people never advance beyond the early stage. With proper monitoring and lifestyle modifications—such as taking specific vitamin supplements, eating a healthy diet, quitting smoking, and managing blood pressure—many people can slow the progression significantly.^[1]

Intermediate dry AMD has a more uncertain outlook. Some people remain at this stage for years without significant vision loss, while others progress to late-stage disease. The good news is that even at this stage, interventions like nutritional supplements have been shown to reduce the risk of advancing to late AMD. Regular monitoring becomes crucial during this phase so that any transition to wet AMD can be caught and treated quickly.^[1]

Late-stage dry AMD, particularly when geographic atrophy develops, typically results in progressive loss of central vision. The rate of vision loss can vary, but once significant areas of the retina have atrophied, that damage is permanent. However, most people retain enough vision to manage many daily activities, especially with visual rehabilitation and adaptive devices.^[1]^[2]

Wet AMD has historically had a more serious prognosis because it can cause rapid vision loss—sometimes over just weeks or months. However, the development of anti-VEGF treatments has dramatically improved outcomes for wet AMD. When caught early and treated promptly with these injections, many people maintain or even improve their vision. The key factor in prognosis for wet AMD is how quickly treatment begins after symptoms appear. Delays in treatment can result in permanent vision loss even if treatment is eventually started.^[6]^[8]

Several factors affect individual prognosis beyond the type and stage of AMD. People who continue smoking after diagnosis tend to have worse outcomes and faster disease progression. Those with AMD in both eyes face more significant challenges with daily activities than those with the disease in only one eye. Cardiovascular health, overall nutrition, and genetic factors also influence how quickly the disease advances.^[2]

An important aspect of prognosis is quality of life. While vision loss from AMD can’t typically be reversed, many people adapt successfully using low-vision aids, better lighting, technology assistance, and visual rehabilitation. With proper support and accommodations, most people with AMD continue to live independently and maintain a good quality of life, even with significant central vision loss.^[12]

Survival rate

The term “survival rate” isn’t typically applied to age-related macular degeneration because it’s not a life-threatening disease. AMD itself doesn’t affect lifespan—people with AMD have normal life expectancies. The condition affects vision, not overall health or mortality.^[2]

What doctors do measure is “vision survival”—how many people maintain functional vision over time. For wet AMD treated with anti-VEGF medications, studies have shown that many patients can preserve their vision when treatment begins promptly. These treatments have greatly improved vision outcomes since they became available in 2005, giving patients a much better chance of maintaining their central vision to read, drive, recognize faces, and continue normal activities.^[6]

For dry AMD, approximately 90% of people with the condition have this form, and most progress slowly through the stages. Not everyone with early or intermediate dry AMD will advance to the late stage that causes severe vision loss. Taking preventive measures—particularly the AREDS2 vitamin supplement formula for those with intermediate AMD—has been shown to reduce the risk of progression to advanced stages by about 25%.^[2]^[10]

Age-related macular degeneration is currently the leading cause of significant vision loss in people over 60 in developed countries, affecting nearly 20 million Americans and an estimated 200 million people worldwide. As populations continue to age globally, the number of people with AMD is expected to reach 288 million by 2040. However, ongoing research into new treatments and better diagnostic methods continues to improve the outlook for people diagnosed with this condition.^[4]^[2]

#1 Clinical Trials Search in Europe